Mutant Allele of CD44 (rs8193C>T) and Pum2 Regulatory Element as A Prognosis Factor of Prostate Neoplasms: A Case-Control and In Silico Studies
暂无分享,去创建一个
[1] K. Ghaedi,et al. CD44 Gene rs8193 C Allele Is Significantly Enriched in Gastric Cancer Patients , 2019, Cell journal.
[2] Dan Xie,et al. 5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs , 2019, Nature Cell Biology.
[3] Shan Li,et al. Association of CD44 polymorphisms and susceptibility to HBV‐related hepatocellular carcinoma in the Chinese population , 2019, Journal of clinical laboratory analysis.
[4] A. F. Campese,et al. Stem-like and highly invasive prostate cancer cells expressing CD44v8-10 marker originate from CD44-negative cells , 2018, Oncotarget.
[5] Xiao-Qian Lin,et al. Association of Single-Nucleotide Polymorphisms of CD44 Gene with Susceptibility to Breast Cancer in Chinese Women , 2018, Medical science monitor : international medical journal of experimental and clinical research.
[6] Matthew R. Cooperberg,et al. Epidemiology of prostate cancer , 2017, World Journal of Urology.
[7] R. D. Mittal,et al. Cluster of Differentiation 44 (CD44) Gene Variants: A Putative Cancer Stem Cell Marker in Risk Prediction of Bladder Cancer in North Indian Population , 2016, Indian Journal of Clinical Biochemistry.
[8] E. Rakha,et al. Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance , 2016, Front. Oncol..
[9] Xixi He,et al. Long Non-Coding RNA ucoo2kmd.1 Regulates CD44-Dependent Cell Growth by Competing for miR-211-3p in Colorectal Cancer , 2016, PloS one.
[10] Yao-sheng Liu,et al. Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis , 2015, Medical science monitor : international medical journal of experimental and clinical research.
[11] T. Gruenberger,et al. Variations in Genes Involved in Dormancy Associated with Outcome in Patients with Resected Colorectal Liver Metastases Original Articles Annals of Oncology , 2022 .
[12] V. Lokeshwar,et al. The Role of CD44 in Disease Pathophysiology and Targeted Treatment , 2015, Front. Immunol..
[13] M. Srougi,et al. Expression profile of standard and variants forms of CD44 related to prostate cancer behavior , 2015, The International journal of biological markers.
[14] J. Turánek,et al. Regulation of alternative splicing of CD44 in cancer. , 2014, Cellular signalling.
[15] W. Duan,et al. CD44 variant 6 is associated with prostate cancer metastasis and chemo‐/radioresistance , 2014, The Prostate.
[16] J. Catto,et al. BPH and prostate cancer risk , 2014, Indian journal of urology : IJU : journal of the Urological Society of India.
[17] Yinghao Sun,et al. Genome-wide association studies on prostate cancer: the end or the beginning? , 2013, Protein & Cell.
[18] A. Toland,et al. The Impact of 3′UTR Variants on Differential Expression of Candidate Cancer Susceptibility Genes , 2013, PloS one.
[19] J. V. Van Etten,et al. Human Pumilio Proteins Recruit Multiple Deadenylases to Efficiently Repress Messenger RNAs* , 2012, The Journal of Biological Chemistry.
[20] Burton B. Yang,et al. The non-coding 3′ UTR of CD44 induces metastasis by regulating extracellular matrix functions , 2012, Journal of Cell Science.
[21] M. Kahn,et al. Common Cancer Stem Cell Gene Variants Predict Colon Cancer Recurrence , 2011, Clinical Cancer Research.
[22] Laura H. Tang,et al. Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma , 2011, International journal of cancer.
[23] Ling Fang,et al. Expression of CD44 3′-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis , 2010, Nucleic acids research.
[24] Hagit Shatkay,et al. F-SNP: computationally predicted functional SNPs for disease association studies , 2007, Nucleic Acids Res..
[25] C. P. Morris,et al. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. , 2006, Carcinogenesis.
[26] H. Grönberg,et al. Genetic Analysis of the RNASEL Gene in Hereditary, Familial, and Sporadic Prostate Cancer , 2004, Clinical Cancer Research.
[27] K. Heider,et al. CD44v6: a target for antibody-based cancer therapy , 2004, Cancer Immunology, Immunotherapy.
[28] P. Noble,et al. CD44 deficiency leads to enhanced neutrophil migration and lung injury in Escherichia coli pneumonia in mice. , 2002, The American journal of pathology.
[29] S. Esnault,et al. Y Box-Binding Factor Promotes Eosinophil Survival by Stabilizing Granulocyte-Macrophage Colony-Stimulating Factor mRNA1 , 2001, The Journal of Immunology.
[30] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[31] S. Goodison,et al. CD44 cell adhesion molecules. , 1999, Molecular pathology : MP.
[32] M. Becich,et al. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. , 1999, Cancer research.
[33] K. Kinzler,et al. Genetic instabilities in human cancers , 1998, Nature.
[34] H. Degrendele,et al. Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity. , 1998, The Journal of clinical investigation.
[35] T. H. van der Kwast,et al. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] K. Heider,et al. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas , 1996, Cancer Immunology, Immunotherapy.
[37] G. Fields,et al. CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. , 1996, Molecular biology of the cell.
[38] Martin Hofmann,et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells , 1991, Cell.
[39] W. Carter,et al. Structural homology between lymphocyte receptors for high endothelium and class III extracellular matrix receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[40] C. Heldin,et al. Involvement of hyaluronan and CD44 in cancer and viral infections. , 2019, Cellular signalling.